Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, arising from
immature lymphocytes that show uncontrolled proliferation and arrested differentiation …

Tremendous strides have been made in the molecular and cytogenetic classification of
acute lymphoblastic leukemia based on gene expression profiling data, leading to an …

The molecular hallmark of childhood acute lymphoblastic leukemia (ALL) is characterized by
recurrent, prognostic genetic alterations, many of which are cryptic by conventional …

Philadelphia chromosome-like (Ph-like) ALL is a recent subtype of acute lymphoblastic
leukemia. Although it does not express the BCR-ABL fusion gene, it has a behavior like true …

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subset of
high-risk B-ALL associated with high relapse risk and inferior clinical outcomes across the …

Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-
rearranged (JAK2 r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to …

Acute lymphoblastic leukemia (ALL) with hyperleukocytosis at diagnosis is associated with
early morbidity and mortality due to complications of leukostasis. Of 535 pediatric ALL …

Philadelphia chromosome (Ph), named after the city where it was first described, was
described for the first time by Nowell and Hungerford in 1960, in two patients who had lost …

Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk
subset of B-cell ALL with a spectrum of underlying genetic alterations that activate kinase or …

Discussion The ZBTB20 protein is a member of the BTB (Broad complex, Tramtrack, Bric-a-
brac)–ZF (zinc finger) family that acts primarily as transcriptional repressors and is involved …